Table 4. UV-vis/NIR imaging agents with fluorescent dyes.
Imaging modality | Dye/contrast agent | Means of incorporation | Major polymer backbone | Responsive size change/degradability | Responsive imaging property | Formulation method a | Size (nm) | Targeting group | Cells/in vivo work | Therapeutics | Ref. |
UV-vis | 5-Aminofluorescein (5-AF), 7-amino-4-methyl coumarin (AMC), or QDs | Conjugation | Chitosan and PAA crosslinked with MBA | N/A | N/A | A + D | 180 | N/A | In vivo lymphatic node mapping of Balb/c mice | Doxorubicin, or Vascular endothelial growth factor C | 117 |
UV-vis | Fluorescein isothiocyanate | Conjugation | Poly(amidoamine) dendrimers and alginate crosslinked with Ca2+ | pH | N/A | E + B | 433 | N/A | Uptake and cytotoxicity on CAL-72 cells | Doxorubicin | 118 |
UV-vis | 8-Hydroxypyrene-1-carbaldehyde (HPC) | Encapsulation | Polyurethane | — | Change in emission wavelength as a function of pH | B | 92 | N/A | Uptake in NIH/3T3 fibroblast cells | N/A | 19 |
UV-vis/NIR | DMDP-M | Encapsulation | Crosslinked Pluronic F127 | — | Fluorescence turned “on” in presence of thiols | B | 45 | N/A | Uptake in NIH/3T3 fibroblasts | N/A | 123 |
UV-vis | Self-fluorescent abietane | As part of polymer matrix | Poly(abietane methacrylate) crosslinked with PEGDA | N/A | N/A | A | 90–135 | Folic acid | Uptake in MCF-7 cells | Doxorubicin | 120 |
UV-vis | Self-fluorescent ALC linker | Electrostatic encapsulation | Branched PEI crosslinked by aldehyde-l-cystine (ALC) linker | Thiols | Decrease in pH and presence of reducing agents lowers the fluorescence | B | 200 | N/A | Transfection in multiple cell lines | pDNA | 121 |
UV-vis | Rhodamine B | As part of polymer matrix | P(NIPAM-co-RhBUA) crosslinked with MBA | Temperature | Increased in fluorescence in presence of Cr3+ and increased temperature | A | 117 (20 °C) and 50 (40 °C) | N/A | N/A | N/A | 122 |
NIR fluorescence | Cyanine dye | Conjugation | Azide-functionalized PEG methyl ether crosslinked with l-cystine-N-carboxy anhydride | Reducing environment | N/A | B | 210 | N/A | N/A | Doxorubicin | 127 |
NIR-797 isothiocyanate | Conjugation | Methacrylated carboxymethyl cellulose crosslinked with disulfide linkage-containing crosslinkers | Reducing environment | N/A | B | 192 | N/A | NIR fluorescence imaging of H22 tumor-bearing mice | Doxorubicin | 126 | |
IRDye800 | Conjugation | Amine-cholesteryl-group-bearing pullulan | N/A | N/A | C | 30 | N/A | SLN Mapping in mice and pigs | N/A | 130 and 131 | |
ICG | Conjugation | ICG–HA conjugate | HAdase | Fluorescence turn “On” in presence of HAdase | C | 189 | HA | Tumor and SLN imaging of MDA-MB-231 tumor bearing mice | N/A | 134 | |
ICG | Conjugation | Self-assembled ICG–HA conjugate with surface further crosslinked with disulfide linkage-containing crosslinkers | HAdase | Fluorescence turn “On” in presence of HAdase | C + B | 293 | N/A | Imaging of front paw of mice that are injected with nanogels pre-incubated with HAdase | N/A | 135 | |
ICG | Conjugation | HA + poly(beta-amino)ester (PBAE) + ICG | pH | Fluorescence turn “On” in presence of HAdase | D | 73 (pH 7.4) and 15 (pH 5.5) | HA | Uptake in MDA-MB-231 breast cancer cells | N/A | 136 | |
Ga-porphyrin | As crosslinkers | α,ω-Diazide/hydroxyl PEG and α,ω-difolate/azidePEG crosslinked by Ga-TPPPP | N/A | — | B | 110 | Folate | — | N/A | 137 |
a Formulation methods: refer to Fig. 1.